Influential Leapfrog Group Jumps In To Rate 5,600 Surgery Centers
In the wake of a KHN/USA Today Network investigation, Leapfrog will check the safety and quality of outpatient centers.
The independent source for health policy research, polling, and news.
In the wake of a KHN/USA Today Network investigation, Leapfrog will check the safety and quality of outpatient centers.
Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.
Although many health policies are set in Washington, states also have a big stake in making sure their residents have access to affordable and effective health care. Julie Rovner of Kaiser Health News joins a panel on the 1A radio broadcast looking at recent moves by states on health issues.
Drug pricing is a top issue in the run-up to the midterm elections.
The private health plans that are an alternative to government-run Medicare continue to grow despite the Affordable Care Act’s cuts of billions of dollars in funding.
Turning 65 is far more life-changing than turning 21 ever was.
Support from family and community appear to shield Latinos from rising suicide rates, researchers say.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.
As the number of Americans with dementia rises, health professionals grapple with how to talk to patients about gun safety at home.
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
The Trump administration announces that the average price for insurance offered to people buying their own coverage on federal exchanges is going down.
Consumers favor ACA’s safeguards on the promise that patients who have health problems can get insurance. In the heat of the midterm campaigns, politicians in both parties agree, but their arguments don’t always add up.
When a young Navy lieutenant died following low-risk childbirth, her husband claimed military doctors botched her care. But his wrongful death claim was dismissed because of a 1950 ruling that bars active-duty service members from suing the U.S. government — for any reason.
A ballot initiative in Maine proposes that free home care services be available to all residents who need help with at least “one daily activity.”
Federal officials are proposing that Medicare pay doctors for a 10-minute “check-in” call with beneficiaries. But many doctors already do this for free, and the plan would require a cost-sharing charge of many patients.
Congress approved two bills last month that prohibit provisions keeping pharmacists from telling patients when they can save money by paying the cash price instead of the price negotiated by their insurance plan.
These young adults are looking for medical care that is convenient, fast and offers cost transparency. They frequently seek treatment at retail clinics, urgent care centers or other options.
Addiction experts argue that buprenorphine, which drug users buy on the street, actually saves lives because it is used in place of more dangerous substances, like heroin and fentanyl.
Just weeks before midterm elections, a move by federal health officials spotlights a contentious issue: the use of human fetal tissue in research. Here’s what you need to know to understand the debate.
Subscribe to KFF Health News' free Morning Briefing.
Noticias en español
© 2026 KFF